Curatis (CURN.SW)

Executive Summary

Curatis is a Swiss publicly traded biopharmaceutical company dedicated to developing innovative therapies for rare and severe diseases, with a primary focus on oncology and autoimmune disorders. Leveraging its proprietary technology platform, the company aims to create novel drug candidates that address high unmet medical needs. Although still early-stage without approved commercial products, Curatis holds potential in its pipeline and technology. Its valuation of approximately $125 million reflects market expectations for its preclinical and clinical programs. The company's success hinges on advancing its candidates through clinical development and securing partnerships or financing to support ongoing research. Investors should monitor progress in its lead programs and any strategic collaborations that could validate its platform.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 1/2 clinical trial for lead oncology candidate55% success
• Q3 2026Announcement of partnership or licensing deal for autoimmune program40% success
• TBDEquity financing or grant to extend cash runway70% success